Serum metabolic signatures of fulminant type 1 diabetes

Weiping Jia, Wei Jia, Jingyi Lu, Jian Zhou, Yuqian Bao, Tianlu Chen, Yinan Zhang, Aihua Zhao, Yunping Qiu, Guoxiang Xie, Congrong Wang

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Fulminant type 1 diabetes (FT1DM) is a relatively new clinical entity featured by acute destruction of pancreatic beta cells. Clinical consequences of FT1DM could be fatal when timely medications are not provided, suggesting the particular importance of rapid and accurate diagnosis. Here we report a serum metabonomics study of FT1DM patients, together with healthy control subjects (NC), type 2 diabetes (T2DM), classic type 1 diabetes (T1DM), and diabetic ketoacidosis (DKA) patients, with the aim of discovering metabolic markers associated with FT1DM. A total of 79 subjects were enrolled (22 NC, 22 T1DM, 22 T2DM, 8 DKA and 5 FT1DM) and the serum metabolic profiling of fasting blood samples was performed using gas chromatography time-of-flight mass spectrometry (GC-TOFMS) coupled with multivariate and univariate statistical analyses. Serum metabolites differentially expressed in FT1DM relative to NC, or to T2DM, T1DM and DKA were identified. Three metabolite markers, 5-oxoproline, glutamate, and homocysteine, were significantly altered among FT1DM, T2DM, T1DM, and DKA. In addition, the three metabolite markers, 5-oxoproline, glutamate, and homocysteine, presented similar patterns of distribution across groups. The results showed that the metabolic signatures of FT1DM identified in this study could be of potential clinical significance for the accurate diagnosis of FT1DM.

Original languageEnglish (US)
Pages (from-to)4705-4711
Number of pages7
JournalJournal of Proteome Research
Volume11
Issue number9
DOIs
StatePublished - Sep 7 2012
Externally publishedYes

Fingerprint

Diabetic Ketoacidosis
Medical problems
Metabolites
Type 1 Diabetes Mellitus
Pyrrolidonecarboxylic Acid
Homocysteine
Glutamic Acid
Serum
Gas chromatography
Metabolomics
Mass spectrometry
Insulin-Secreting Cells
Blood
Gas Chromatography
Type 2 Diabetes Mellitus
Fasting
Mass Spectrometry
Healthy Volunteers

Keywords

  • biomarker
  • FT1DM
  • fulminant type 1 diabetes
  • metabolomics
  • metabonomics
  • serum

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Jia, W., Jia, W., Lu, J., Zhou, J., Bao, Y., Chen, T., ... Wang, C. (2012). Serum metabolic signatures of fulminant type 1 diabetes. Journal of Proteome Research, 11(9), 4705-4711. https://doi.org/10.1021/pr300523x

Serum metabolic signatures of fulminant type 1 diabetes. / Jia, Weiping; Jia, Wei; Lu, Jingyi; Zhou, Jian; Bao, Yuqian; Chen, Tianlu; Zhang, Yinan; Zhao, Aihua; Qiu, Yunping; Xie, Guoxiang; Wang, Congrong.

In: Journal of Proteome Research, Vol. 11, No. 9, 07.09.2012, p. 4705-4711.

Research output: Contribution to journalArticle

Jia, W, Jia, W, Lu, J, Zhou, J, Bao, Y, Chen, T, Zhang, Y, Zhao, A, Qiu, Y, Xie, G & Wang, C 2012, 'Serum metabolic signatures of fulminant type 1 diabetes', Journal of Proteome Research, vol. 11, no. 9, pp. 4705-4711. https://doi.org/10.1021/pr300523x
Jia W, Jia W, Lu J, Zhou J, Bao Y, Chen T et al. Serum metabolic signatures of fulminant type 1 diabetes. Journal of Proteome Research. 2012 Sep 7;11(9):4705-4711. https://doi.org/10.1021/pr300523x
Jia, Weiping ; Jia, Wei ; Lu, Jingyi ; Zhou, Jian ; Bao, Yuqian ; Chen, Tianlu ; Zhang, Yinan ; Zhao, Aihua ; Qiu, Yunping ; Xie, Guoxiang ; Wang, Congrong. / Serum metabolic signatures of fulminant type 1 diabetes. In: Journal of Proteome Research. 2012 ; Vol. 11, No. 9. pp. 4705-4711.
@article{0d4e1e48e03e4a5486cf0f46abce5ac2,
title = "Serum metabolic signatures of fulminant type 1 diabetes",
abstract = "Fulminant type 1 diabetes (FT1DM) is a relatively new clinical entity featured by acute destruction of pancreatic beta cells. Clinical consequences of FT1DM could be fatal when timely medications are not provided, suggesting the particular importance of rapid and accurate diagnosis. Here we report a serum metabonomics study of FT1DM patients, together with healthy control subjects (NC), type 2 diabetes (T2DM), classic type 1 diabetes (T1DM), and diabetic ketoacidosis (DKA) patients, with the aim of discovering metabolic markers associated with FT1DM. A total of 79 subjects were enrolled (22 NC, 22 T1DM, 22 T2DM, 8 DKA and 5 FT1DM) and the serum metabolic profiling of fasting blood samples was performed using gas chromatography time-of-flight mass spectrometry (GC-TOFMS) coupled with multivariate and univariate statistical analyses. Serum metabolites differentially expressed in FT1DM relative to NC, or to T2DM, T1DM and DKA were identified. Three metabolite markers, 5-oxoproline, glutamate, and homocysteine, were significantly altered among FT1DM, T2DM, T1DM, and DKA. In addition, the three metabolite markers, 5-oxoproline, glutamate, and homocysteine, presented similar patterns of distribution across groups. The results showed that the metabolic signatures of FT1DM identified in this study could be of potential clinical significance for the accurate diagnosis of FT1DM.",
keywords = "biomarker, FT1DM, fulminant type 1 diabetes, metabolomics, metabonomics, serum",
author = "Weiping Jia and Wei Jia and Jingyi Lu and Jian Zhou and Yuqian Bao and Tianlu Chen and Yinan Zhang and Aihua Zhao and Yunping Qiu and Guoxiang Xie and Congrong Wang",
year = "2012",
month = "9",
day = "7",
doi = "10.1021/pr300523x",
language = "English (US)",
volume = "11",
pages = "4705--4711",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Serum metabolic signatures of fulminant type 1 diabetes

AU - Jia, Weiping

AU - Jia, Wei

AU - Lu, Jingyi

AU - Zhou, Jian

AU - Bao, Yuqian

AU - Chen, Tianlu

AU - Zhang, Yinan

AU - Zhao, Aihua

AU - Qiu, Yunping

AU - Xie, Guoxiang

AU - Wang, Congrong

PY - 2012/9/7

Y1 - 2012/9/7

N2 - Fulminant type 1 diabetes (FT1DM) is a relatively new clinical entity featured by acute destruction of pancreatic beta cells. Clinical consequences of FT1DM could be fatal when timely medications are not provided, suggesting the particular importance of rapid and accurate diagnosis. Here we report a serum metabonomics study of FT1DM patients, together with healthy control subjects (NC), type 2 diabetes (T2DM), classic type 1 diabetes (T1DM), and diabetic ketoacidosis (DKA) patients, with the aim of discovering metabolic markers associated with FT1DM. A total of 79 subjects were enrolled (22 NC, 22 T1DM, 22 T2DM, 8 DKA and 5 FT1DM) and the serum metabolic profiling of fasting blood samples was performed using gas chromatography time-of-flight mass spectrometry (GC-TOFMS) coupled with multivariate and univariate statistical analyses. Serum metabolites differentially expressed in FT1DM relative to NC, or to T2DM, T1DM and DKA were identified. Three metabolite markers, 5-oxoproline, glutamate, and homocysteine, were significantly altered among FT1DM, T2DM, T1DM, and DKA. In addition, the three metabolite markers, 5-oxoproline, glutamate, and homocysteine, presented similar patterns of distribution across groups. The results showed that the metabolic signatures of FT1DM identified in this study could be of potential clinical significance for the accurate diagnosis of FT1DM.

AB - Fulminant type 1 diabetes (FT1DM) is a relatively new clinical entity featured by acute destruction of pancreatic beta cells. Clinical consequences of FT1DM could be fatal when timely medications are not provided, suggesting the particular importance of rapid and accurate diagnosis. Here we report a serum metabonomics study of FT1DM patients, together with healthy control subjects (NC), type 2 diabetes (T2DM), classic type 1 diabetes (T1DM), and diabetic ketoacidosis (DKA) patients, with the aim of discovering metabolic markers associated with FT1DM. A total of 79 subjects were enrolled (22 NC, 22 T1DM, 22 T2DM, 8 DKA and 5 FT1DM) and the serum metabolic profiling of fasting blood samples was performed using gas chromatography time-of-flight mass spectrometry (GC-TOFMS) coupled with multivariate and univariate statistical analyses. Serum metabolites differentially expressed in FT1DM relative to NC, or to T2DM, T1DM and DKA were identified. Three metabolite markers, 5-oxoproline, glutamate, and homocysteine, were significantly altered among FT1DM, T2DM, T1DM, and DKA. In addition, the three metabolite markers, 5-oxoproline, glutamate, and homocysteine, presented similar patterns of distribution across groups. The results showed that the metabolic signatures of FT1DM identified in this study could be of potential clinical significance for the accurate diagnosis of FT1DM.

KW - biomarker

KW - FT1DM

KW - fulminant type 1 diabetes

KW - metabolomics

KW - metabonomics

KW - serum

UR - http://www.scopus.com/inward/record.url?scp=84866133036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866133036&partnerID=8YFLogxK

U2 - 10.1021/pr300523x

DO - 10.1021/pr300523x

M3 - Article

VL - 11

SP - 4705

EP - 4711

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 9

ER -